Patent SG-11201909081Y-A (SG)
Title: Anti-ilt4 antibodies and antigen-binding fragments
Inventor: ZUNIGA LUIS
IPC: A61K39/395
Filed: 2018-04-05
Abstract: E 400 E 300 0 200 0 E 12 100 0 7 14 21 28 35 42 Treatment 20 mpk 49 56 63 0 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT omit °nolo momm ono iflo (10) International Publication Number WO 2018/187518 Al FIG.17 (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/026160 (22) International Filing Date: 05 April 2018 (05.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/483,019 07 April 2017 (07.04.2017) US (71) Applicants: MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue, Rahway, New Jer- sey 07065-0907 (US). AGENUS INC. [US/US]; 3 Forbes Road, Lexington, Massachusetts 02421 (US). (72) Inventors; and (71) Applicants (for US only): ZUNIGA, Luis, A. [US/US]; 901 S. California Avenue, Palo Alto, California 94304 (US). JOYCE-SHAIKH, Barbara [US/US]; 901 S. California Avenue, Rahway, New Jersey 94304 (US). BLANUSA, Milan [RS/US]; 3 Forbes Road, Lexington, Massachu- setts 02421 (US). SCHUSTER, Andrea Claudia [DE/US]; 3 Forbes Road, Lexington, Massachusetts 02421 (US). SCHULTZE, Kornelia [DE/US]; 3 Forbes Road, Lexing- ton, Massachusetts 02421 (US). (74) Common Representative: MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (54) Title: ANTI-ILT4 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS ••••• !so G1/04 -v- ILT4 1E1—IgG1 - - A -- ILT4 1E1 —IgG1 (N297Q) ILT4 1E1 —IgG4 - ILT4 2A6—IgG4 A ILT4 2C1—IgG4 - A - ILT4 2D5—IgG4 1-1 00 1-1 N 00 1-1 (57) : The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for © treating or preventing cancer in a subject; and methods of making such antibodies and fragments. o [Continued on next page] WO 2018/187518 Al MIDEDIMOMOIDEIREEMOMOHOMMOHOMEEN (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))